Insights

A&M Newsletters
Comprehensive and timely perspectives, on the topics that matter to you, sent straight to your inbox.
Created

Reclaiming the Patient Relationship: MaineHealth's Moonshot for Cognitive Medicine

August 11, 2026
What if the biggest innovation in healthcare wasn't a new technology, but a new way of delivering primary care? Returning guest @Andy Mueller, M.D., CEO of MaineHealth joins A&M Healthcare Industry Group's Aaron Bujnowski, DSc, FACHE and @David Shulkin, M.D. to share how MaineHealth is challenging traditional care models with an approach that empowers care teams, removes unnecessary barriers and puts patients back at the center of care.
Thought Leadership

European Due Diligence Report 2026

August 11, 2026
As geopolitical uncertainty and AI disruption reshape the PE landscape, private equity investors are transforming how they evaluate deals. A new A&M report reveals the critical shift toward operational resilience, integrated diligence, and the tools redefining PE due diligence in today's volatile environment.
Thought Leadership

The Dual Mandate: AI for IA & IA for AI

August 7, 2026
Alvarez & Marsal hosted The Dual Mandate: AI for IA & IA for AI, bringing together senior Internal Audit leaders for an evening of practical discussion on how organizations are navigating AI adoption while strengthening governance and assurance.
Thought Leadership

DHS Adds 43 Entities to the UFLPA Entity List — Enforcement Reach Extends Deep into Metals, Pharmaceuticals, and Food Supply Chains

August 6, 2026
On August 3, 2026, the Department of Homeland Security, as Chair of the Forced Labor Enforcement Task Force (FLETF), published an updated UFLPA Entity List adding 43 new entities (two of which appear on two separate sub-lists) and making technical corrections to two existing entries. The consolidated list now stands at 187 entities. Goods mined, produced, or manufactured, wholly or in part, by a listed entity are subject to the UFLPA's rebuttable presumption of forced labor and are prohibited from entry under 19 U.S.C. § 1307, effective immediately upon listing.
Thought Leadership

Section 232 Pharmaceutical Duties: UK Rate Cut to Zero, and the Origin and Section 301 Questions That Follow

August 5, 2026
Effective July 31, 2026, the additional Section 232 tariff on patented pharmaceuticals that are products of the United Kingdom was reduced from 10% to zero (heading 9903.04.63), implementing the U.S.–UK Pharmaceutical Pricing Arrangement. Because UK patented pharmaceuticals remain subject to Section 232 (at a 0% rate), they also fall within the Section 232 carve-out from the new Section 301 forced labor tariffs — so qualifying UK patented product should face no additional duty under either regime.
Thought Leadership

Better Data, Better Exits: The New Playbook for Wealth and Insurance Platform Roll-Ups

August 5, 2026
There’s a new value creation imperative for private equity (PE) firms and corporates seeking to roll up financial technology (FinTech) and data platform acquisitions, especially in the extended higher interest rate environment. Many of the traditional value enhancement strategies still matter, but operational platforming—integrating tech, data, and systems—can be a defining competitive advantage in roll-ups.